Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$0.26
-$0.14(-35.52%)
At close: 4:00 PM EDT
$0.26
-$0.14(-35.52%)
Day’s Range― - ―
52-Week Range$0.19 - $3.20
Previous CloseN/A
Volume5.72M
Average Volume (3M)309.34K
Market Cap
$3.01M
Enterprise Value$14.55
Total Cash (Recent Filing)$1.84M
Total Debt (Recent Filing)$3.32M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.33
Shares Outstanding14,391,944
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSharp TTM revenue growth indicates improving commercial traction and greater adoption of VIVO. Sustained expansion could improve operating leverage as the installed customer base and procedure volumes increase.
Gross Margin PotentialA roughly 48% gross margin shows that VIVO can generate meaningful gross profit before corporate costs. If revenue scales, this margin profile may provide a foundation for improving profitability over time.
Manageable LeverageModerate leverage limits balance-sheet pressure and preserves some financial flexibility for operations. The improvement from prior-year leverage reduces near-term solvency risk, provided losses do not continue eroding equity.
Bears Say
Persistent Net LossesLosses remain extremely large relative to revenue, showing that the current cost structure is not supported by the commercial base. Continued losses could delay breakeven and erode equity even if revenue keeps growing.
Heavy Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding. This constrains investment capacity and leaves growth dependent on additional financing until revenue scale or costs improve materially.
External Funding DependenceThe financing supports liquidity and capital-structure changes, but its use for working capital highlights dependence on external capital. Repeated structured financings may create dilution and limit strategic flexibility.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.19 and its highest was $3.20 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $3.01M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.
How were Catheter Precision’s earnings last quarter?
Catheter Precision released its earnings results on Aug 17, 2026. The company reported -$0.923 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 14,391,944 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Catheter Precision reported an EPS of -$0.923 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -18.571%.
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
Technical Analysis
Ownership Overview
0.10%
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.85% Public Companies and
Individual Investors